MPC 0920

Drug Profile

MPC 0920

Alternative Names: MPC-0920

Latest Information Update: 25 Sep 2009

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 25 Sep 2009 Discontinued - Phase-I for Thrombosis in USA (PO)
  • 29 Jan 2008 Myriad completes a phase I trial in volunteers in USA
  • 17 Aug 2007 MPC 0920 is still in phase I trials for thrombosis in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top